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Background: COPD exacerbations are responsible for the morbidity and mortality of this 
disease. The relationship between exacerbations and patient-related clinical outcomes is not 
clearly understood.
Methods: A retrospective analysis of two 1-year, placebo-controlled clinical trials with 
tiotropium 18 µg daily was conducted to examine relationships between exacerbations and 
other clinical outcomes. The relationship between FEV1, St. George’s Respiratory Question-
naire (SGRQ), and the transition dyspnea index (TDI) were examined based on the frequency 
of exacerbations (0, 1, 2, 2).
Results: 921 patients participated in the trials (mean age 65 years, mean FEV1 = 1.02 L (39% 
predicted). The percent change from baseline in FEV1 in the tiotropium group was +12.6%, 
+12.0%, +2.1% and +8.9%; and in the placebo group was -3.4%, -3.4%, -5.7% and -6.7% 
for exacerbation frequencies of 0, 1, 2, 2, respectively. Compared with baseline, the largest 
improvement in SGRQ occurred in patients with no exacerbations. In the placebo group, there 
was a significant association between an increased frequency of exacerbations and worsening 
SGRQ scores. A reduction in exacerbation rates of 4.4% to 42.0% such as that shown in this 
study cohort was associated with meaningful changes in questionnaire based instruments.
Conclusions: In the placebo-treated patients increased frequency of exacerbations was associated 
with larger decrements in FEV1, TDI, and SGRQ. A reduction in the frequency of exacerbations 
is associated with changes that are considered meaningful in these clinical outcomes.
Keywords: exacerbations, chronic obstructive pulmonary disease, FEV1, dyspnea, quality of life
Introduction
Exacerbations of COPD are known to be associated with increased morbidity and 
mortality and to have a significant socioeconomic impact.1–6 Patients with frequent 
exacerbations often experience impaired quality of life and a faster decline in lung 
function over time.7,8 Severe exacerbations that lead to hospitalization constitute a 
risk for mortality both during the hospitalization and during the subsequent year.9–11 
Furthermore, the number of exacerbation may be the factor associated with increased 
mortality.12 In addition, exacerbations, including those requiring hospitalization, are 
the largest direct cost driver for the treatment of COPD in most countries.5,6,13 In the 
United States in 2000, direct expenditures for COPD were approximately US$18 
billion with almost 50% of the costs due to hospitalizations.5 While any reduction in 
frequency or duration of COPD exacerbations may be advantageous, it is important 
to consider the relationship of exacerbations to other variables of interest in patients 
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relevant to COPD such as the St. George’s Respiratory 
Questionnaire (SGRQ), and the transition dyspnea index 
(TDI). Furthermore, we examined whether such outcomes 
can be used to explore the concept of a threshold for clinically 
meaningful reductions in exacerbation frequency.
Methods
Retrospective post-hoc analyses of two previously reported 
1-year placebo-controlled clinical trials with tiotropium 
18 µg daily18 were performed 1) to examine the relationship 
of exacerbation frequency with spirometry, dyspnea, and 
health status, and 2) to explore the potential for defining an 
MCID for exacerbations by examining changes in exacer-
bation frequency according to currently assumed MCID for 
measures of dyspnea and health status.
study design
The trials used a randomized, double-blind and parallel-group 
design. Tiotropium was administered at 18 µg once daily 
via the HandiHaler® device (Boehringer Ingelheim GmbH 
and Co. KG, Ingelheim, Germany) and the trials were 
conducted in 50 centers in the United States.18 All patients 
who participated in these trials were at least 40 years of age, 
had a diagnosis of COPD with a smoking history of at 
least 10 pack-years and had objective documentation of 
airflow limitation (forced expiratory volume in 1 second 
[FEV1]  60 to 65% predicted, FEV1/forced vital capacity 
[FVC]  70%). The major inclusion and exclusion criteria 
for the trials were designed to include patients with stable 
COPD, exclude those with asthma, and exclude those with 
potentially unstable, serious co-morbid conditions that 
would interfere with either the interpretation of the results 
or the ability of the patient to complete studies of 1 year 
duration.
During the treatment period, all patients who partici-
pated in these one-year studies, including those random-
ized to placebo, were permitted to take their previously 
prescribed respiratory medications for COPD with the 
exception of long-acting beta-adrenergic agonists (LABAs) 
and inhaled anticholinergic agents. All patients were 
provided with a short-acting beta-agonist (albuterol) to 
use as-needed for rescue relief of symptoms. Patients 
were permitted medications to treat exacerbations as medi-
cally indicated. Clinic visits were scheduled at 6 weeks, 
and on four other occasions (equally spaced) during the 
approximately 1-year treatment period. All patients signed 
written informed consent before any study procedures 
were performed.
The threshold at which an intervention has a clinically 
meaningful effect is often referred to as the “minimal 
clinically important difference” (MCID) or the “minimal 
clinically important treatment effect” (MCITE). Jaeschke 
et al define the MCID as “the smallest difference in score in 
the domain of interest which patients perceive as beneficial 
and which would mandate, in the absence of troublesome 
side-effects and excessive cost, a change in the patient’s 
management.”14 For example, the St. George’s Respiratory 
Questionnaire (SGRQ), used to measure health status in 
COPD patients, has been validated and is used extensively 
in COPD. For the SGRQ, a change of 4 units (from a 100 
point scale) is considered the MCID.15,16 There is cur-
rently no MCID identified for a change in exacerbations 
of COPD; however, the occurrence of a single exacerba-
tion is implicitly meaningful in terms of its clinical and 
cost impact and subsequent outcomes. It can therefore be 
argued that it is inappropriate to determine an MCID for 
exacerbations.
Interventions that reduce the risk of experiencing an 
exacerbation or reduce the frequency of exacerbations 
would be expected to have a consequent desirable impact 
on morbidity, health care costs and possibly on mortality. 
To date, several interventions have been proposed as 
potentially reducing exacerbations of COPD.1 However, the 
recognition of a positive effect does not necessarily translate 
into a broad recommendation for maintenance use to prevent 
or reduce exacerbations. The effect must be balanced with 
the known safety profile of the intervention and the clinical 
relevance of the effect.
An analysis of trials in the clinical development of 
tiotropium allows the opportunity to examine the relation-
ship between exacerbation and other relevant outcomes 
and whether the concept of an MCID could be applied to 
exacerbations of COPD. Tiotropium is an inhaled anticho-
linergic for the treatment of COPD that leads to a minimum 
of 24-hour bronchodilation with once-daily dosing. This 
sustained bronchodilation is thought to be a result of the 
prolonged dissociation half-life from the muscarinic M3 
receptor (approximately 35 hours).17 Previously reported 
clinical trials of 1-year and of 6-months duration have 
demonstrated that tiotropium improves lung function, 
dyspnea, exercise tolerance and health status.18–22 In addition, 
tiotropium trials have shown consistent effects on reduc-
ing exacerbations of COPD.18–20,23,24 The objective of the 
present report is to use the data from two 1-year tiotropium 
vs placebo-controlled clinical trials18 to examine the rela-
tionship of frequency of exacerbations and other outcomes International Journal of COPD 2009:4 247
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Assessments
The primary endpoint was morning pre-dose FEV1.18 Other 
assessments (including dyspnea, as needed albuterol, health 
status and exacerbations) were secondary outcomes.
FEV1 and FVC were measured at clinic visits using 
calibrated spirometers and results were assessed in accor-
dance with American Thoracic Society criteria.25
Dyspnea was assessed using the Baseline and Transition 
Dyspnea Index.26 The Dyspnea Index questionnaire consists 
of three domains (functional impairment, magnitude of task, 
and magnitude of effort). Scores from the three domains are 
summed to determine a focal score. This instrument was 
administered at baseline to determine the Baseline Dyspnea 
Index (BDI), an assessment of the baseline severity of dys-
pnea, and at defined intervals throughout the studies to deter-
mine the Transition Dyspnea Index (TDI), an assessment of 
change from baseline. A change of 1 unit in the focal score 
was used to represent a clinically meaningful change.27,28
The St. George’s Respiratory Questionnaire (SGRQ) was 
used as the disease specific measurement of health status.16 
The SGRQ consists of a 76 item questionnaire divided into 
three domains (symptoms, activities, and impacts). The total 
score is a composite of the three domains. The SGRQ was 
administered at baseline and at intervals throughout each 
study. A change of 4 units in the total score was used to 
represent a clinically meaningful change.15,16
exacerbations of COPD
Exacerbations were defined “as a complex of respiratory 
events (ie, cough, wheezing, dyspnea or sputum produc-
tion) lasting 3 days. These events were generally treated 
with antibiotics and/or oral steroids”18,19 and reported by the 
investigator as an adverse event.
Data analysis
Analyses used for primary and secondary outcomes have been 
previously reported.18 The statistical model used for measures of 
spirometry, dyspnea and SGRQ was the analysis of covariance 
with terms for treatment and center with baselines as covari-
ates. All patients with a non-missing baseline and at least one 
non-missing post-baseline values were included in the analyses. 
This can result in different number of patients analyzed for 
the various outcomes. None of the analyses were corrected 
for multiple comparisons. The incidence of exacerbations 
and hospitalizations was analyzed using a logistic regression 
adjusting for extent of exposure. The number of exacerbations 
and hospitalizations was analyzed using the Wilcoxon-Mann-
Whitney test. Statistical significance was defined as P  0.05. 
Analysis assessing the relationship  
of exacerbations to other outcomes
Multiple post-hoc analyses were conducted to explore asso-
ciations of the occurrence of exacerbations or the frequency 
of exacerbations with other outcomes recorded as part of 
the clinical trials.
The categorization of patients into different frequencies 
of exacerbations (0, 1, 2, 2) was determined without adjust-
ment for patient exposure to treatment. Associations between 
exacerbation frequency with changes in FEV1 and changes 
in SGRQ scores over one year were tested using an analysis 
of covariance model with terms for treatment, categories 
and treatment categories interaction. Values are expressed 
as means ± SE unless otherwise specified. Spearman’s rank 
correlation coefficient was determined (with the correspond-
ing P-value for testing difference from zero) for within 
group changes in FEV1 and SGRQ total and impacts scores 
to exacerbation frequency (0, 1, 2, 2).
Analysis exploring an MCID for exacerbations
In an attempt to define a clinically meaningful reduction in 
exacerbations, the number of exacerbations per patient year 
was assessed according to categories of change in dyspnea 
(TDI focal score), and health status (SGRQ total score). 
Categories were defined based on the following assumed 
MCIDs: TDI focal score (1 unit), and SGRQ total score 
(4 units). For the TDI focal score, patients were divided 
into groups according to a change of  –1, 0, or  +1 unit. 
For the SGRQ total score, patients were divided into groups 
according to a change of  +4, 0 to +4, 0 to –4 or  –4 units. 
In addition, to examine associations with corresponding 
MCIDs for other outcomes in a relatively stable population, 
the percent change in number of exacerbations per patient 
year was calculated for the placebo group according to shifts 
from one category of scores to another category for each 
instrument. Changes from baseline could not be assessed as 
there was no collection of the frequency of exacerbations in 
the period prior to randomization.
Results
A total of 921 patients with COPD were randomized into 
these trials, 550 of whom were treated with tiotropium. The 
mean age was approximately 65 years with approximately 
65% being men. The mean FEV1 was 1.02 L (39% predicted). 
There were no differences in exposure to study drug between 
tiotropium and placebo groups. Tiotropium was associated 
with improvements in lung function, dyspnea, and health-
status and reduced the requirement for as-needed albuterol. International Journal of COPD 2009:4 248
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These results are described in detail in a previous publication.18 
Tiotropium was associated with a reduction in exacerbations 
and hospitalizations related to exacerbations.18
To examine the effect of exacerbations on other outcomes, 
the changes in FEV1, and SGRQ total scores were assessed 
according to frequency of exacerbations.
Decline in lung function
The mean baseline FEV1 in subgroups with exacerbation 
frequency of 0, 1, 2, or 2 over the study period for 
tiotropium vs placebo were 1.06 L vs 1.05 L, 0.96 L vs 
0.95 L, 0.90 L vs 0.88 L, and 0.88 L vs 0.88 L, respec-
tively. Tiotropium improved mean FEV1 in patients in all 
categories of frequency of COPD exacerbations (Table 1). 
However, in the tiotropium group, increasing frequency 
of exacerbations was generally associated with a lower 
absolute degree of improvement (Table 1). With tiotropium, 
the percent change from baseline (calculated as percent of 
mean change from baseline versus mean baseline) in FEV1 
was +12.6%, +12.0%, +2.1% and +8.9% for exacerbation 
frequencies of 0, 1, 2, 2, respectively. The placebo group 
showed a reduction in FEV1 at all frequencies of COPD 
exacerbations. In the placebo group, increasing frequency 
of exacerbations was generally associated with a higher rate 
of decline over one year. In the placebo group, the percent 
change from baseline in FEV1 was –3.4%, –3.4%, –5.7% 
and –6.7% for exacerbation frequencies of 0, 1, 2, 2, respec-
tively. Confounding by the different baselines (ie,lower FEV1 
with increased exacerbation frequency) cannot be ruled out. 
The correlation between changes in FEV1 and exacerbation 
frequency was –0.131 (P = 0.003) in the tiotropium group 
and –0.027 (P = 0.628) in the placebo group.
health status
The SGRQ total scores were assessed according to frequency 
of exacerbations to allow examination of the association of 
exacerbations on health status. Despite the adverse effect 
of exacerbations, all mean SGRQ scores in tiotropium 
patients remained lower than baseline (ie, improved) for 
1 year (Table 2). Compared with baseline, the largest 
improvement in mean SGRQ occurred in patients with no 
exacerbations; compared with placebo, the greatest benefit 
was noted in patients with the most frequent exacerbations. 
In the placebo group, there was an association between an 
increased frequency of exacerbations and worsening SGRQ 
scores. As with FEV1 decline, confounding by the different 
baselines (ie, lower FEV1 with increased exacerbation 
frequency) cannot be ruled out. The correlation between 
SGRQ impacts and total scores and exacerbation frequency 
in the tiotropium group was 0.011 (P = 0.805) and 0.049 
(P = 0.271) respectively. The corresponding correlation 
coefficients in the placebo group were 0.116 (P = 0.037) 
and 0.150 (P = 0.007).
Association of exacerbations  
to MCIDs for other clinical outcomes
Frequencies of exacerbations per patient year were assessed 
in the tiotropium and placebo groups according to currently 
recognized MCIDs for dyspnea (TDI focal score), and health-
status (SGRQ total score). Improvements in these instrument 
scores were associated with reductions in the frequency of 
exacerbations, with larger questionnaire score improvements 
associated with larger reductions in exacerbations (Table 3).
In considering whether the change equal to the MCID 
for one of the instruments (TDI  1 unit, SGRQ  4 units) 
can be associated to a corresponding change in the frequency 
of exacerbations, the placebo group serves as a relatively 
stable population who has not received a new intervention. 
The change in frequency of exacerbations was calculated for 
the placebo group according to shifts equal to the MCIDs in 
questionnaire scores.
A TDI focal score change of  +1 unit was associated 
with a 28.7% less exacerbations per patient year in mean 
frequency of exacerbations compared with those who had 
a change of 0; those who had a change of 0 had a 42.0% 
reduction in mean frequency of exacerbations compared with 
those who had a change of  -1 unit.
An SGRQ total score change of -4 units was associated 
with a 38.5% relative reduction in mean frequency of 
exacerbations compared with those who had a change of 
0 to  +4 units; those who had a change of 0 to  -4 units had 
a 4.4% relative reduction in mean frequency of exacerbations 
compared with those who had a change of 4 units.
The analysis suggests that a reduction in exacerbations 
can be examined in terms of changes associated with other 
Table 1 Mean (se) changes in FeV1 (mL) in the tiotropium and 
placebo groups over 1 year according to exacerbation frequency
Tiotropium (n = 518) Placebo (n = 328)
Exacerbation 
frequency
N ∆ FEV1 (mL) N ∆ FEV1 (mL)
0 327 +134 (12) 179 -36 (16)*
1 111 +115 (20) 92 -32 (22)*
2 44 +19 (32) 34 -50 (37)
2 36 +78 (36) 23 -59 (44)*
*P  0.05 tiotropium vs placebo.International Journal of COPD 2009:4 249
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meaningful outcomes. The analysis is limited by lower 
numbers in the various subgroups. A relative reduction in 
exacerbation rates of 4.4% to 42.0% such as that shown in 
this study cohort was associated with meaningful changes 
in questionnaire based instruments.
Discussion
We sought to examine the relationship of exacerbations and 
clinical outcomes. Furthermore, we wanted to evaluate if the 
clinical relevance of a reduction in exacerbations in patients 
participating in controlled clinical trials could be determined. 
In the present analysis the frequency of exacerbations was 
shown to be directionally associated with changes in spirom-
etry, dyspnea, and health status of the patient’s COPD. Our 
data suggest that reductions in the frequency of exacerbations 
rates of 4.4% to 42.0% were associated with meaningful 
changes in questionnaire based instruments.
Based on the significant health care costs, and increased 
morbidity and mortality related to exacerbations of COPD,1–4 
it could be argued that any reduction in exacerbations is mean-
ingful. Examination of the relationships of exacerbations with 
patient-related outcomes is worth in understanding the clinical 
impact of a reduction or increase in frequency of exacerbations. 
While the associations of exacerbations with other outcomes 
are recognized, it is not proven in a clinical trial that a change 
in the frequency of exacerbations has an impact on other out-
comes that can be considered meaningful. Knowledge of such 
associations with exacerbations could help to determine the 
threshold at which a therapeutic intervention is warranted. For 
example, an extremely small (eg, 1%) decrease in exacerba-
tions may be statistically significant but not of sufficient clinical 
importance to justify prescription of an intervention based on 
costs, side effects and other considerations (ie, efficacy or lack 
of efficacy on other endpoints). In this study we are showing 
that the reduction of patient’s COPD exacerbation is also 
associated with an impact in patient-related outcomes.
In the consideration of any analysis attempting to define 
clinically important changes, the definition of an exacerbation 
needs to be clear and regarded as meaningful. The specific 
definition of COPD exacerbations in published clinical trials 
has varied, although in general the definitions fall within the 
framework proposed by a consensus definition published 
in 2000 as follows: “a sustained worsening of the patient’s 
condition, from the stable state and beyond normal day-to-day 
variations that is acute in onset and necessitates a change in 
regular medication in a patient with underlying COPD.”29 
The definition is consistent with the American Thoracic 
Society and European Respiratory Society definition pub-
lished in 2004 30 and the revised GOLD statement.1 There are 
essentially three components of a definition for exacerbations: 
a) an implied minimal time frame of the event (ie, day-to-day), 
b) a degree of change in respiratory symptoms (ie, beyond 
normal variations, acute in onset), and c) a statement that an 
intervention is required (ie, change in regular medication).
There have been relatively few studies looking at the rela-
tionship between COPD exacerbations and quality of life in 
patients with COPD. Seemungal and colleagues showed that 
exacerbations were more frequent in patients with frequent 
previous exacerbations (odds ratio = 5.5, P = 0.001). Using the 
median number of exacerbations, patients were classified as 
infrequent exacerbators (0–2) or frequent exacerbators (3–8). 
SGRQ total score was significantly worse in frequent exacer-
bators (mean difference 14.8, P  0.001). In multiple regres-
sion analyses, exacerbation frequency was strongly correlated 
with SGRQ total score and component scores. Conners and 
colleagues evaluated quality-of-life outcomes in their study 
of patients hospitalized with acute exacerbations of COPD.10 
At 6 months patients were interviewed about their activities 
of daily living, and 54% required assistance with at least one 
activity of daily living and 49% considered their health status 
to be fair or poor. No analysis was conducted on the relation-
ship between readmissions and perceived quality of life.
Both of the aforementioned investigations support the con-
cept that COPD exacerbations have a negative effect on qual-
ity of life in patients with COPD. This association suggests 
that quality of life is impaired not only in patients who are hos-
pitalized for acute exacerbations of COPD, but also in patients 
who experience frequent exacerbations that are treated in the 
ambulatory care setting. Hence, while a survival benefit might 
be expected from a reduction in COPD exacerbations requir-
ing hospitalization, an improvement in quality of life might be 
an anticipated outcome of a reduction in overall exacerbations, 
including those that do not require hospitalization. The pres-
ent analysis corroborates the hypothesis that exacerbations 
Table 2 Mean (se) changes in the st. georges Respiratory 
Questionnaire total scores in the tiotropium and placebo groups 
over 1 year according to exacerbation frequency
Tiotropium (n = 516) Placebo (n = 324)
Exacerbation 
frequency
N Total score N Total score
0 326 –4.0 (0.7) 175 –1.5 (0.9)**
1 111 –2.7 (1.1) 92 0.9 (1.2)**
2 44 –1.3 (1.8) 34 2.6 (2.0)
2 35 –3.4 (2.0) 23 5.3 (2.5)**
**P  0.05 tiotropium vs placebo.International Journal of COPD 2009:4 250
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impact health-related quality-of-life and demonstrates that 
interventions that reduce exacerbations are associated with 
improvements in quality of life.
Donaldson et al evaluated the relationship between 
exacerbation frequency and decline in lung function 
in 109 patients (mean age 68.1 years, mean FEV1 1.00 
(0.7–1.3 L) recruited from outpatient clinics in the UK.31 The 
mean exacerbation rate was 2.92 exacerbations/year; patients 
with 2.92 exacerbations per year were considered frequent 
exacerbators; those with 2.92 exacerbations per year were 
considered infrequent exacerbators. FEV1 data were evalu-
ated over 4 years in 16 frequent exacerbators compared with 
16 infrequent exacerbators. In this subgroup, frequent exacer-
bators were younger (median age 61.6 vs 71.5 years, P = 0.03) 
and a higher number of frequent exacerbators were current 
smokers (9/16 vs 1/16 respectively). The mean rate of decline 
in FEV1 in the total cohort was 36 mL/year. The mean rate of 
decline in FEV1 per year was greater in the frequent compared 
with infrequent exacerbators (40.1 ml/year vs 32.1 ml/year, 
respectively, P  0.05). The present study supports the conten-
tion that exacerbations can accelerate the loss of lung function 
over time and suggests that such changes may possibly be 
modified by interventions reducing exacerbations; however, 
it is recognized that firm conclusions cannot be drawn from 
the present analysis given the relatively short time of study 
(1 year) and the retrospective nature of the analysis.
In considering an MCID for exacerbations, we recognize 
that the present retrospective analyses has several limitation 
and do not establish a precise association of the frequency or 
severity of exacerbations with a MCID in a given dyspnea or 
health status instrument. A limitation to the present analysis 
is that there was no adjustment for potential confounders 
such as FEV1. In addition, based on the published literature, 
there is no precedent for establishing a clinically meaningful 
reduction in COPD exacerbations and it is not the purpose of 
the present analyses to state that this should be a prerequisite 
for evaluating interventions. It should also be noted that 
MCID metrics designed from health status are not generally 
considered appropriate to apply to a clinical outcome such as 
exacerbations. MCID is a metric established to confer meaning 
to patient-reported outcome scales that have no intrinsic 
meaning (eg, quality of life scales from 0 to 1). It is reasonable 
to consider that it is inappropriate to seek an MCID for an 
outcome for which any occurrence is meaningful and has 
significant associated clinical impact and cost consequence. 
Nevertheless, this type of analysis was considered in the present 
manuscript because of the historic difficulty in establishing 
the cumulative impact of exacerbations and hence the value 
of their avoidance. It remains reasonable to contend that given 
the overall consequences of exacerbations on patients with 
COPD and the lack of treatments that reduce the frequency 
of exacerbations, an intervention that repeatedly has shown 
positive effects should be considered highly desirable.
In summary, clinical data suggest that an increased 
frequency of exacerbations is associated with worsening 
quality of life, and a more rapid decline in spirometry over 
time. Our analysis demonstrated a wide range of changes 
in the frequency of exacerbations that were associated 
with clinically meaningful changes in clinical outcomes. 
The present post-hoc analysis should be viewed cautiously. 
Table 3 number of exacerbations per patient year according to treatment group and end-of-treatment transition dyspnea index (TDI) 
focal score, and change from baseline in st. georges Respiratory Questionnaire (sgRQ 0total score)
Tiotropium Placebo
N treated No. of exacerbations Patient years Rate N treated No. of exacerbations Patient years Rate
∆ TDI
Focal score
  ≤-1 81 88 63.0 1.40 80 91 60.5 1.50
  0 193 108 156.5 0.69 152 106 122.5 0.87
  ≥1 233 123 198.5 0.62 93 49 79.1 0.62
∆ SGRQ
Total score
≥4 118 82 96.6 0.85 113 102 89.4 1.14
≥0,4 65 39 51.2 0.76 48 33 37.8 0.87
 -4, 0 79 51 63.6 0.80 65 58 53.4 1.09
 –4 254 148 214.1 0.69 98 54 81.1 0.67International Journal of COPD 2009:4
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More data from large databases are required to continue to 
explore the issues raised in the present discussion.
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